Clinical trials: Second Line Treatment of Gastric Cancer
Advanced Gastric Cancer
Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer
Liposomal irinotecan, intravenous infusion 90min, d1: Grade 1:50mg/m2 Grade 2:60mg/m2 Grade 3:70mg/m2 Albumin-paclitaxel, 150mg/m2, intravenous infusion, d1 DLT was observed for 2 weeks (the first cycle).
- Trial name
- NCT06486545
- Testing
- Irinotecan Hydrochloride Liposome Injection；Paclitaxel For Injection (Albumin Bound)
- Volunteers
- 18 people
- Sponsor
- Hunan Cancer Hospital
Gastric Carcinoma
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
This study is being performed to evaluate the efficacy and safety of capecitabine in combination with tesetaxel versus capecitabine in combination with placebo as second-line treatment for patients with gastric cancer.
- Trial name
- TESEGAST (NCT01573468)
- Testing
- Tesetaxel, Capecitabine
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 580 people
- Sponsor
- Genta Incorporated
Gastric Cancer
Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.
A phase I/II study is conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using CPT-11 and Paclitaxel in pre-treated patients with metastatic gastric…
- Trial name
- NCT00209612
- Testing
- Taxol, Campt, Topotesin
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
This is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab, Lenvatinib and Paclitaxel in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma after first-line…
- Trial name
- NCT05585580
- Testing
- Serplulimab, Lenvatinib, Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome
- Where
- 7 sites in China
- Volunteers
- 59 people
- Sponsor
- Qilu Hospital of Shandong University
Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA
The purpose of this study is to determine whether apatinib plus irinotecan can improve progression free survival compared with single irinotecan in patients with advanced gastric cancer or adenocarcinoma of esophagogastric…
- Trial name
- NCT03030937
- Testing
- Apatinib, Irinotecan
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fujian Cancer Hospital
Gastric Cancer, Gastroesophageal Junction Region (GEJ) Cancer
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
The main purpose of this study is to evaluate the safety and efficacy of the combination therapy of ramucirumab and nivolumab in participants with advanced or recurrent unresectable gastric or GEJ cancer.
- Trial name
- NCT02999295
- Testing
- Ramucirumab, Nivolumab
- Where
- Japan
- Volunteers
- 46 people
- Sponsor
- National Cancer Center, Japan
Gastric Cancer
Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer
Currently, standard treatment options for gastric cancer failed to first-line treatment include monotherapy with paclitaxel/irinotecan/docetaxel/albumin paclitaxel, or paclitaxel combined with ramucirumab.
- Trial name
- NCT06349967
- Testing
- Nab-paclitaxel Combined With Cadonilimab (AK104)
- Volunteers
- 59 people
- Sponsor
- West China Hospital
Stomach Neoplasms
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
This study employs a randomized, controlled, exploratory clinical trial design, with a planned enrollment of 66 patients who have previously failed systemic chemotherapy for recurrent/metastatic gastric cancer,
- Trial name
- NCT07309185
- Testing
- Adebrelimab, Irinotecan, Malic acid Famitinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shandong Tumor Hospital
Advan'ce'd, Advanced
IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
This study is for patients with advanced or metastatic gastric cancer whose disease has worsened after first-line systemic therapy.
- Trial name
- NCT07361991
- Testing
- IBI363, Bevacizumab, Nab-paclitaxel
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Gastric Cancer
Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
This is a prospective, single-center, open, single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib combined with TAS102 for second-line treatment of advanced gastric cancer.
- Trial name
- NCT06102785
- Testing
- Fruquintinib, TAS102
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Cancer, Randomized Controlled Study
Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
The study is a multicenter, open-label, randomized controlled clinical study. The purpose of the study is to evaluate the efficacy and safety of apatinib combined with chemotherapy versus chemotherapy in second-line gastric…
- Trial name
- NCT05029453
- Testing
- Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Stomach Neoplasm
RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment
This is a phase II study to evaluate RAD001 (Everolimus) in terms of 4-month progression-free survival rate (primary end-point) and response rate, toxicity, and overall survival (secondary end-points) in patients with metastatic…
- Trial name
- NCT00729482
- Testing
- RAD001
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Asan Medical Center
Recurrent/Advanced Gastric Cancer
Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression
Clinical Indication : HER mutated or HER2 Amplification/Overexpression in Gastric Cancer, 2nd-line Trial Type : Interventional, Open label Treatment Groups : Single arm: Pembrolizumab 200 mg every 3 weeks (Q3W), neratinib at 240…
- Trial name
- NCT05512182
- Testing
- Chemotherapy
- Where
- South Korea
- Sponsor
- Yonsei University
Gastric Cancer, Gastroesophageal Junction Cancer
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
This study will evaluate overall survival of nimotuzumab in combination with irinotecan compared to irinotecan alone in subjects with EGFR overexpressed advanced gastric or gastroesophageal junction cancer.
- Trial name
- NCT01813253
- Testing
- Irinotecan, Nimotuzumab
- Where
- 37 sites in Japan, South Korea and 1 more
- Volunteers
- 400 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
Cancer
Study of Afuresertib Combined With Paclitaxel in Gastric Cancer
This is a Phase Ib, open-label, dose-escalation study to determine the Maximal tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) for the combination of afuresertib and paclitaxel in subjects with recurrent…
- Trial name
- NCT02240212
- Testing
- Afuresertib, Paclitaxel
- Where
- 5 sites in South Korea, Taiwan
- Volunteers
- 29 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent and Metastatic Gastric Cancer
A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients
Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor; Apatinib is an oral selective VEGFR inhibitor. This open-label, dose finding phase I trial studies the tolerability and the best dose of Fluzoparib in…
- Trial name
- NCT03026881
- Testing
- Fluzoparib, Apatinib, Paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
HER-2 Positive Gastric Cancer, Gastrooesophageal Cancer
Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
The investigators are doing this research program to find out if the investigational drug, afatinib which is a medication known to block the function of the ErbB2 protein might help standard chemotherapy, in particular…
- Conditions
- HER-2 Positive Gastric Cancer, Gastrooesophageal Cancer, Esophageal Cancer
- Trial name
- NCT02274012
- Testing
- Afatinib, Paclitaxel
- Sponsor
- Columbia University
Advanced Gastric Cancer
Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer
This study is to evaluate the tolerance of albumin paclitaxel combined with apatinib and Camrelizumab in the second-line treatment of advanced gastric cancer to determine the maximum tolerable dose (MTD) of the combination.
- Trial name
- NCT04286711
- Testing
- Albumin-paclitaxel, Apatinib, Camrelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- China Medical University, China
Gastric Cancer, Gastroesophageal Junction Cancer
Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer
For the gastric cancer, paclitaxel is recommended as salvage standard treatment. Afatinib is a novel, potent, small ErbB family blocker that covalently binds and irreversibly blocks signaling through activated EGFR, HER2 and…
- Trial name
- NCT02501603
- Testing
- afatinib, paclitaxel
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Yonsei University
Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma of the Stomach
Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma
Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma following first-line therapy with platinum and fluoropyrimidine doublet with or without anthracycline, docetaxel or trastuzumab
- Trial name
- AIO-STO-0218 (NCT03966118)
- Testing
- Avelumab, Ramucirumab, Paclitaxel
- Where
- Germany
- Volunteers
- 59 people
- Sponsor
- P. C. Thuss-Patience